Celltrion’s Truxima Has 30 pct Market Share in Britain
SEOUL, Aug. 1 (Korea Bizwire) — An affiliate of South Korean biopharmaceutical firm Celltrion Inc. said Tuesday that its biosimilar drug Truxima accounts for 30 percent of the Britain market. Truxima, a reference to Roche’s Mabthera, also known as Rituxan, has become a presence in the European country since its launch in April, Celltrion Healthcare [...]